The RAVE Network Attack

Cyber-attacks are an ever-present threat to our modern, technologically dependent world. This looming shadow of a disaster waiting to happen has led companies to invest heavily into their software resiliency and network defenses. However, many companies, especially small ones, have forgotten the danger of an insider threat, or at least how an insider threat could be emulated. Anything on the inside of a network automatically has a higher level of trust because most companies’ defenses have only gone as far as to protect their perimeter and educate their employees. What if an outside attacker was able to gain physical access for just a brief time to the inside of a small business? Say, in a waiting room or consultation? RAVE stands for Remote Attack Vector Engine, and is a device designed to test this flaw. RAVE is a small Raspberry Pi 0, disguised as any common workplace device, that an attacker can plant in a business’s network to attack from the inside. By connecting RAVE to an internal ethernet port, a secure reverse OpenVPN connection is automatically created to a Middleman Server over common HTTPS traffic through port 443 and kept persistent. An operator is then able to connect into RAVE through the Middleman Server. The operator can then use tools installed on the device to launch network scans, perform brute force password attacks on network devices and services, take over more devices on the network, and steal data from the company. By using this device, penetration testers can help companies develop better security practices to keep their network safe from infiltration and exploitation

Free light chains as an emerging biomarker in saliva::biological variability and comparisons with salivary IgA and steroid hormones

BackgroundSalivary free light chains (FLCs) are an emerging biomarker in health and behavioural research. However, little is known regarding biological variability of salivary FLCs and how they relate to other established salivary biomarkers. This study aimed to investigate the diurnal and day-to-day variation of salivary FLCs and their relationship with salivary IgA and steroid hormones.MethodsA total of 46 healthy adults participated in studies exploring the biological variability of FLCs. Diurnal variation was investigated by collecting saliva samples immediately upon waking, 0.5 h, 3 h, 6 h, 9 h and 14 h post-waking. Saliva samples were assessed for FLCs, IgA, cortisol and dehydroepiandrosterone (DHEA). Between-day variation in FLCs and IgA was assessed by collecting saliva samples immediately upon waking for seven consecutive days. Participants underwent a dental examination to exclude oral health as a potential confounding variable. Within and between-person day-to day variation was explored in relation to a range of different factors: awakening time, sleep, exercise, well-being and alcohol consumption.ResultsSalivary secretion rates of FLCs decreased following waking and up to 3 h post-waking and then plateaued. This same pattern was observed for IgA. DHEA was stable upon waking and higher levels were seen in the morning with significantly lower levels thereafter. Cortisol levels significantly increased 0.5 h post-waking then continued to decline across the day. FLCs were significantly correlated with IgA but not cortisol or DHEA. Both FLCs and IgA parameters showed day-to-day variability, with coefficients of variation ≥ 40%. Earlier waking time was significantly correlated with higher FLC and IgA secretion rates. Inter-person differences in saliva parameter variability were observed but the degree of variation in FLCs and IgA was related within person. Inter-person day-to-day variation appeared to be uninfluenced by lifestyle or behavioural factors.ConclusionsSaliva FLCs secretion exhibits diurnal fluctuation that mirrors IgA fluctuation. Findings strongly indicate salivary FLC secretion is orchestrated by local plasma cells. FLCs and IgA both showed notable variability day-to-day, which was similar within person and influenced by awakening time. FLCs offer a promising adjunct to IgA in the measurement of oral immune activation

Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity

OBJECTIVES Myeloma is characterised by the presence of monoclonal immunoglobulin (M-protein) and the free light chain (FLC) in blood. We investigated whether these M-proteins and FLC are detectable in myeloma patients' saliva to evaluate its utility for non-invasive screening and monitoring of haematological malignancies. METHODS A total of 57 patients with monoclonal gammopathy and 26 age-matched healthy participants provided paired serum and saliva samples for immunoglobulin characterisation and quantification. RESULTS Myeloma patients had IgG or IgA M-protein levels ranging up to five times and FLC levels up to a thousand times normal levels of polyclonal immunoglobulins. Despite these highly elevated levels, only two IgG and no IgA M-proteins or FLC could be detected in paired saliva samples. Most patients had reduced levels of serum polyclonal immunoglobulins, but all had normal levels of salivary IgA. CONCLUSIONS Immunoglobulin transfer from blood is not determined by levels in the systemic circulation and more likely dictated by periodontal inflammation and the integrity of the oral epithelium. Immunoglobulins secreted by bone marrow plasma cells do not substantially enter saliva, which represents a poor medium for myeloma diagnosis. These findings, along with normal salivary IgA levels despite systemic immunoparesis, support a strong partitioning of oral from systemic humoral immunity

The Global Magneto-Ionic Medium Survey (GMIMS): The brightest polarized region in the Southern sky at 75cm and its implications for Radio Loop II

Using the Global Magneto-Ionic Medium Survey (GMIMS) Low-Band South (LBS) southern sky polarization survey, covering 300 to 480 MHz at 81 arcmin resolution, we reveal the brightest region in the Southern polarized sky at these frequencies. The region, G150-50, covers nearly 20deg$^2$, near (l,b)~(150 deg,-50 deg). Using GMIMS-LBS and complementary data at higher frequencies (~0.6--30 GHz), we apply Faraday tomography and Stokes QU-fitting techniques. We find that the magnetic field associated with G150-50 is both coherent and primarily in the plane of the sky, and indications that the region is associated with Radio Loop II. The Faraday depth spectra across G150-50 are broad and contain a large-scale spatial gradient. We model the magnetic field in the region as an expanding shell, and we can reproduce both the observed Faraday rotation and the synchrotron emission in the GMIMS-LBS band. Using QU-fitting, we find that the Faraday spectra are produced by several Faraday dispersive sources along the line-of-sight. Alternatively, polarization horizon effects that we cannot model are adding complexity to the high-frequency polarized spectra. The magnetic field structure of Loop II dominates a large fraction of the sky, and studies of the large-scale polarized sky will need to account for this object. Studies of G150-50 with high angular resolution could mitigate polarization horizon effects, and clarify the nature of G150-50.Comment: 25 pages, 14 figures. Accepted for publication in MNRA

Design and testing of a four rod crab cavity for High Luminosity LHC

A 4-rod deflecting structure is proposed as a possible crab cavity design for the LHC high luminosity upgrade. Crab cavities are required for the LHC luminosity upgrade to provide a greater bunch overlap in the presence of a crossing angle, but must fit in the existing limited space. The structure has two parallel sections consisting of two longitudinally opposing quarter-wave rods, where each rod has the opposite charge from each of its nearest neighbors. The structure is transversely compact because the frequency is dependent on the rod lengths rather than the cavity radius. Simulations were undertaken to investigate the effect of rod shape on surface fields, higher order multipole terms and induced wakefields in order to obtain the optimal rod shape. The simulation results presented show that the addition of focus electrodes or by shaping the rods the sextupole contribution of the cavity voltage can be negated; the sextupole contribution is 321.57 mTm/m2, Epeak=27.7 MV/m and Bpeak=63.9 mT at the design voltage of 3 MV. The damping requirements for the LHC are critical and suitable couplers to damp all modes but the operating mode are presented. The results of various testing cycles of the first SRF 4 rod prototype cavity are presented and show that the cavity has reached the required transverse voltage of 3 MV

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

BACKGROUND: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer. METHODS: We did a phase 3, two-group, open-label, multicentre, randomised clinical trial at 92 hospitals in England, Scotland, Wales, Germany, France, and Sweden. Eligible patients were aged 18 years or older and had undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas (R0 or R1 resection). We randomly assigned patients (1:1) within 12 weeks of surgery to receive six cycles of either 1000 mg/m(2) gemcitabine alone administered once a week for three of every 4 weeks (one cycle) or with 1660 mg/m(2) oral capecitabine administered for 21 days followed by 7 days' rest (one cycle). Randomisation was based on a minimisation routine, and country was used as a stratification factor. The primary endpoint was overall survival, measured as the time from randomisation until death from any cause, and assessed in the intention-to-treat population. Toxicity was analysed in all patients who received trial treatment. This trial was registered with the EudraCT, number 2007-004299-38, and ISRCTN, number ISRCTN96397434. FINDINGS: Of 732 patients enrolled, 730 were included in the final analysis. Of these, 366 were randomly assigned to receive gemcitabine and 364 to gemcitabine plus capecitabine. The Independent Data and Safety Monitoring Committee requested reporting of the results after there were 458 (95%) of a target of 480 deaths. The median overall survival for patients in the gemcitabine plus capecitabine group was 28·0 months (95% CI 23·5-31·5) compared with 25·5 months (22·7-27·9) in the gemcitabine group (hazard ratio 0·82 [95% CI 0·68-0·98], p=0·032). 608 grade 3-4 adverse events were reported by 226 of 359 patients in the gemcitabine plus capecitabine group compared with 481 grade 3-4 adverse events in 196 of 366 patients in the gemcitabine group. INTERPRETATION: The adjuvant combination of gemcitabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma

A Multisite Preregistered Paradigmatic Test of the Ego-Depletion Effect

We conducted a preregistered multilaboratory project (k = 36; N = 3,531) to assess the size and robustness of ego-depletion effects using a novel replication method, termed the paradigmatic replication approach. Each laboratory implemented one of two procedures that was intended to manipulate self-control and tested performance on a subsequent measure of self-control. Confirmatory tests found a nonsignificant result (d = 0.06). Confirmatory Bayesian meta-analyses using an informed-prior hypothesis (δ = 0.30, SD = 0.15) found that the data were 4 times more likely under the null than the alternative hypothesis. Hence, preregistered analyses did not find evidence for a depletion effect. Exploratory analyses on the full sample (i.e., ignoring exclusion criteria) found a statistically significant effect (d = 0.08); Bayesian analyses showed that the data were about equally likely under the null and informed-prior hypotheses. Exploratory moderator tests suggested that the depletion effect was larger for participants who reported more fatigue but was not moderated by trait self-control, willpower beliefs, or action orientation.</p